
GLP-1 Weight Loss: Muscle Loss Not a Unique Risk, Experts Say
At ADA 2026, experts debated GLP-1–driven weight loss and muscle loss. The consensus is that most weight loss with GLP-1s is fat rather than lean mass, with no solid evidence that GLP-1 therapies cause frailty or sarcopenia overall. Concern is greatest for high‑risk groups (older adults, menopausal women, sarcopenic obesity), where large lean-mass losses could be problematic. Measurement issues matter: DEXA often misrepresents skeletal muscle; D3-creatine dilution provides a more direct assessment and links low muscle mass to worse outcomes. Exercise and adequate protein remain essential to preserve muscle, and some patients may improve function despite lean-mass loss. Weight regain can negate benefits, underscoring the need for monitoring and resistance training in older patients; pharmacologic approaches to protect lean mass are in development.



